James Jones, DO
Family Medicine · Toledo, OHNPI 1700226073
Payments from drug & device makers
Across 75 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$213
- AbbVie$156
- Pfizer$137
- Braeburn Inc.$119
- Novo Nordisk$89
- Johnson & Johnson$87
- plus $374 from 15 others
What the payments were for
- Food & beverage$1,16199%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 21 | $213 |
| AbbVie | 9 | $156 |
| Pfizer | 8 | $137 |
| Braeburn Inc. | 1 | $119 |
| Novo Nordisk | 6 | $89 |
| Johnson & Johnson | 6 | $87 |
| GSK | 3 | $53 |
| Lilly USA, LLC | 3 | $45 |
| Endogastric Solutions, Inc | 3 | $34 |
| Boehringer Ingelheim | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Amgen | 2 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| AstraZeneca | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Exact Sciences | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Merck | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRIXADI$119
How this compares
$1,174 in reported general payments places this provider in the 65th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 153 | $222,899 |
| EliquisApixaban | 110 | $111,688 |
| JanuviaSitagliptin Phosphate | 60 | $87,245 |
| JardianceEmpagliflozin | 56 | $84,510 |
| TrulicityDulaglutide | 48 | $73,254 |
| XareltoRivaroxaban | 57 | $65,031 |
| MounjaroTirzepatide | 44 | $56,091 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $29,214 |
| LinzessLinaclotide | 35 | $28,301 |
| FarxigaDapagliflozin Propanediol | 30 | $26,351 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $25,137 |
| RybelsusSemaglutide | 13 | $23,493 |
| JanumetSitagliptin Phos/Metformin Hcl | 25 | $21,344 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,833 |
| Atorvastatin Calcium | 1,135 | $14,541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $89 | $246,392166 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $45 | $129,34592 claims |
| PfizerEliquis | $137 | $111,688110 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Combivent Respimat | $30 | $110,79891 claims |
| MerckJanuvia, Janumet | $14 | $108,58985 claims |
| Johnson & JohnsonXarelto | $87 | $65,03157 claims |
| AbbVieLinzess | $156 | $28,30135 claims |
| AstraZenecaFarxiga | $19 | $26,35130 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $53 | $19,55637 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $6,42715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Toledo
- Henry NaddafToledo$252K
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.